Monopar Therapeutics (MNPR) Cash & Equivalents (2016 - 2020)

Monopar Therapeutics' Cash & Equivalents history spans 5 years, with the latest figure at $18.0 million for Q3 2020.

  • For Q3 2020, Cash & Equivalents rose 300.1% year-over-year to $18.0 million; the TTM value through Sep 2020 reached $18.0 million, up 300.1%, while the annual FY2019 figure was $13.2 million, 91.71% up from the prior year.
  • Cash & Equivalents for Q3 2020 was $18.0 million at Monopar Therapeutics, up from $12.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $18.0 million in Q3 2020 and bottomed at $2.9 million in Q4 2016.
  • The 5-year median for Cash & Equivalents is $7.9 million (2018), against an average of $8.4 million.
  • The largest annual shift saw Cash & Equivalents plummeted 41.0% in 2019 before it soared 300.1% in 2020.
  • A 5-year view of Cash & Equivalents shows it stood at $2.9 million in 2016, then surged by 240.48% to $9.8 million in 2017, then dropped by 29.54% to $6.9 million in 2018, then soared by 91.71% to $13.2 million in 2019, then skyrocketed by 36.09% to $18.0 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Cash & Equivalents are $18.0 million (Q3 2020), $12.5 million (Q2 2020), and $12.6 million (Q1 2020).